Efficacy of a multistep strategy for Helicobacter pylori eradication
2000-01-01 Gasbarrini, A; Ojetti, V; Armuzzi, A; Branca, G; Canducci, F; Torre, Es; Candelli, M; Pastorelli, A; Anti, M; Fedeli, G; Fadda, G; Pola, P; Gasbarrini, G
Clinical trials in luminal Crohn's disease: a historical perspective
2014-01-01 Hindryckx, P; Baert, F; Hart, A; Armuzzi, Alessandro; Panès, J; Peyrin Biroulet, L.
Benefit-risk assessment of golimumab in the treatment of refractory ulcerative colitis
2016-01-01 Pugliese, D; Felice, C; Landi, R; Papa, A; Guidi, L; Armuzzi, A
Advances in extracorporeal detoxification by MARS dialysis in patients with liver failure
2003-01-01 Di Campli, C; Dal Verme, Lz; Andrisani, Mc; Armuzzi, A; Candelli, M; Gaspari, R; Gasbarrini, A
Predictors of clinical response in patients with ulcerative colitis treated with granulocyte-monocyte apheresis: analysis of the apheresis registry data
2012-01-01 Ferraro, Pietro Manuel; D'Ovidio, V; Bresci, G; Astegiano, M; Principi, B; D'Inca', R; Testa, R; Valpiani, D; Guidi, Luisa; Armuzzi, Alessandro; Costa, F; Aratari, A; Vecchi, M; De Franchis, R; Di Leo, V; Ricci, C; Riegler, G; Colombo, E; Repaci, G; Lecis, P; Silla, M; Passalacqua, S.
Hepatic mitochondrial beta-oxidation in patients with nonalcoholic steatohepatitis assessed by C-13-octanoate breath test
2003-01-01 Miele, L; Grieco, A; Armuzzi, A; Candelli, M; Forgione, A; Gasbarrini, G
The effect of oral administration of Lactobacillus GG on antibiotic-associated gastrointestinal side-effects during Helicobacter pylori eradication therapy
2001-01-01 Armuzzi, A; Cremonini, F; Bartolozzi, F; Canducci, F; Candelli, M; Ojetti, V; Cammarota, G; Anti, M; De Lorenzo, A; Pola, P; Gasbarrini, G; Gasbarrini, A
IBD Adalimumab for ulcerative colitis-is the glass half empty or half full?
2011-01-01 Armuzzi, A; Pugliese, D
Infliximab in severe ulcerative colitis: short-term results of different infusion regimens and long-term follow-up
2007-01-01 Kohn, A; Daperno, M; Armuzzi, A; Cappello, M; Biancone, L; Orlando, A; Viscido, A; Annese, V; Riegler, G; Meucci, G; Marrollo, M; Sostegni, R; Gasbarrini, A; Peralta, S; Prantera, C
Pharmacological approaches to the management of alcohol addiction
2002-01-01 Addolorato, G; Armuzzi, A; Gasbarrini, G; De Lorenzi, G; Ancona, C; Abenavoli, L; Parente, A; Leggio, L; Capristo, E; Greco, Av; Janiri, L; Pozzi, G; Taranto, C; Caputo F, ; Bernardi, M; Stefanini, Gf; Foschi, Fg
Microscopic imaging of Inflammatory Bowel Disease (IBD) and Non-IBD Colitis on digital slides: The Italian Group-IBD Pathologists experience
2020-01-01 Salviato, T; Bonetti, Lr; Mangogna, A; Leoncini, G; Cadei, M; Caprioli, F; Armuzzi, A; Daperno, M; Villanacci, V
Long-term scheduled therapy with infliximab in inflammatory bowel disease
2009-01-01 Armuzzi, A; De Vincentis, F; Marzo, M; De Pascalis, B; Roberto, I; Mocci, G; Fiore, F; Leso, V; Fedeli, P; Papa, A; De Vitis, I; Melina, D; Fedeli, G; Gasbarrini, A; Guidi, L
Anti-TNF-alpha therapies do not increase early postoperative complications in patients with inflammatory bowel disease. An Italian single-center experience
2011-01-01 Rizzo, G; Armuzzi, A; Pugliese, D; Verbo, A; Papa, A; Mattana, C; Rapaccini, Gl; Guidi, L; Coco, C
Indicators of suboptimal tumor necrosis factor antagonist therapy in inflammatory bowel disease
2017-01-01 Lindsay, Jo; Armuzzi, A; Gisbert, Jp; Bokemeyer, B; Peyrin-Biroulet, L; Nguyen, Gc; Smyth, M; Patel, H.
Italian Expert Panel on the management of patients with coexisting spondyloarthritis and inflammatory bowel disease
2014-01-01 Olivieri, I; Cantini, F; Castiglione, F; Felice, C; Gionchetti, P; Orlando, A; Salvarani, C; Scarpa, R; Vecchi, M; Armuzzi, Alessandro
Risk of burnout and stress in physicians working in a COVID team: A longitudinal survey
2021-01-01 Dionisi, T; Sestito, L; Tarli, C; Antonelli, M; Tosoni, A; D'Addio, S; Mirijello, A; Vassallo, Ga; Leggio, L; Gasbarrini, A; Addolorato, G; Gemelli Against COVID-19, Group; Armuzzi, A
Frontiers in Drug Research and Development for Inflammatory Bowel Disease
2017-01-01 Currò, D; Pugliese, D; Armuzzi, A
Anti-TNF alpha therapy in the management of extraintestinal manifestation of inflammatory bowel disease
2012-01-01 Andrisani, G; Guidi, L; Papa, A; Armuzzi, A
Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis
2021-01-01 Sandborn, W. J.; Feagan, B. G.; D'Haens, G.; Wolf, D. C.; Jovanovic, I.; Hanauer, S. B.; Ghosh, S.; Petersen, A.; Hua, S. Y.; Lee, J. H.; Charles, L.; Chitkara, D.; Usiskin, K.; Colombel, J.; Laine, L.; Danese, S.; Armuzzi, A; True North Study, Group
A machine-learning parsimonious multivariable predictive model of mortality risk in patients with Covid-19
2021-01-01 Murri, R; Lenkowicz, J; Masciocchi, C; Iacomini, C; Fantoni, M; Damiani, A; Marchetti, A; Sergi, Pda; Arcuri, G; Cesario, A; Patarnello, S; Antonelli, M; Bellantone, R; Bernabei, R; Boccia, S; Calabresi, P; Cambieri, A; Cauda, R; Colosimo, C; Crea, F; De Maria, R; De Stefano, V; Franceschi, F; Gasbarrini, A; Parolini, O; Richeldi, L; Sanguinetti, M; Urbani, A; Zega, M; Scambia, G; Valentini, V; Armuzzi, A; Gremese, E; Gemelli against Covid, Group
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| Efficacy of a multistep strategy for Helicobacter pylori eradication | 1-gen-2000 | Gasbarrini, A; Ojetti, V; Armuzzi, A; Branca, G; Canducci, F; Torre, Es; Candelli, M; Pastorelli, A; Anti, M; Fedeli, G; Fadda, G; Pola, P; Gasbarrini, G | |
| Clinical trials in luminal Crohn's disease: a historical perspective | 1-gen-2014 | Hindryckx, P; Baert, F; Hart, A; Armuzzi, Alessandro; Panès, J; Peyrin Biroulet, L. | |
| Benefit-risk assessment of golimumab in the treatment of refractory ulcerative colitis | 1-gen-2016 | Pugliese, D; Felice, C; Landi, R; Papa, A; Guidi, L; Armuzzi, A | |
| Advances in extracorporeal detoxification by MARS dialysis in patients with liver failure | 1-gen-2003 | Di Campli, C; Dal Verme, Lz; Andrisani, Mc; Armuzzi, A; Candelli, M; Gaspari, R; Gasbarrini, A | |
| Predictors of clinical response in patients with ulcerative colitis treated with granulocyte-monocyte apheresis: analysis of the apheresis registry data | 1-gen-2012 | Ferraro, Pietro Manuel; D'Ovidio, V; Bresci, G; Astegiano, M; Principi, B; D'Inca', R; Testa, R; Valpiani, D; Guidi, Luisa; Armuzzi, Alessandro; Costa, F; Aratari, A; Vecchi, M; De Franchis, R; Di Leo, V; Ricci, C; Riegler, G; Colombo, E; Repaci, G; Lecis, P; Silla, M; Passalacqua, S. | |
| Hepatic mitochondrial beta-oxidation in patients with nonalcoholic steatohepatitis assessed by C-13-octanoate breath test | 1-gen-2003 | Miele, L; Grieco, A; Armuzzi, A; Candelli, M; Forgione, A; Gasbarrini, G | |
| The effect of oral administration of Lactobacillus GG on antibiotic-associated gastrointestinal side-effects during Helicobacter pylori eradication therapy | 1-gen-2001 | Armuzzi, A; Cremonini, F; Bartolozzi, F; Canducci, F; Candelli, M; Ojetti, V; Cammarota, G; Anti, M; De Lorenzo, A; Pola, P; Gasbarrini, G; Gasbarrini, A | |
| IBD Adalimumab for ulcerative colitis-is the glass half empty or half full? | 1-gen-2011 | Armuzzi, A; Pugliese, D | |
| Infliximab in severe ulcerative colitis: short-term results of different infusion regimens and long-term follow-up | 1-gen-2007 | Kohn, A; Daperno, M; Armuzzi, A; Cappello, M; Biancone, L; Orlando, A; Viscido, A; Annese, V; Riegler, G; Meucci, G; Marrollo, M; Sostegni, R; Gasbarrini, A; Peralta, S; Prantera, C | |
| Pharmacological approaches to the management of alcohol addiction | 1-gen-2002 | Addolorato, G; Armuzzi, A; Gasbarrini, G; De Lorenzi, G; Ancona, C; Abenavoli, L; Parente, A; Leggio, L; Capristo, E; Greco, Av; Janiri, L; Pozzi, G; Taranto, C; Caputo F, ; Bernardi, M; Stefanini, Gf; Foschi, Fg | |
| Microscopic imaging of Inflammatory Bowel Disease (IBD) and Non-IBD Colitis on digital slides: The Italian Group-IBD Pathologists experience | 1-gen-2020 | Salviato, T; Bonetti, Lr; Mangogna, A; Leoncini, G; Cadei, M; Caprioli, F; Armuzzi, A; Daperno, M; Villanacci, V | |
| Long-term scheduled therapy with infliximab in inflammatory bowel disease | 1-gen-2009 | Armuzzi, A; De Vincentis, F; Marzo, M; De Pascalis, B; Roberto, I; Mocci, G; Fiore, F; Leso, V; Fedeli, P; Papa, A; De Vitis, I; Melina, D; Fedeli, G; Gasbarrini, A; Guidi, L | |
| Anti-TNF-alpha therapies do not increase early postoperative complications in patients with inflammatory bowel disease. An Italian single-center experience | 1-gen-2011 | Rizzo, G; Armuzzi, A; Pugliese, D; Verbo, A; Papa, A; Mattana, C; Rapaccini, Gl; Guidi, L; Coco, C | |
| Indicators of suboptimal tumor necrosis factor antagonist therapy in inflammatory bowel disease | 1-gen-2017 | Lindsay, Jo; Armuzzi, A; Gisbert, Jp; Bokemeyer, B; Peyrin-Biroulet, L; Nguyen, Gc; Smyth, M; Patel, H. | |
| Italian Expert Panel on the management of patients with coexisting spondyloarthritis and inflammatory bowel disease | 1-gen-2014 | Olivieri, I; Cantini, F; Castiglione, F; Felice, C; Gionchetti, P; Orlando, A; Salvarani, C; Scarpa, R; Vecchi, M; Armuzzi, Alessandro | |
| Risk of burnout and stress in physicians working in a COVID team: A longitudinal survey | 1-gen-2021 | Dionisi, T; Sestito, L; Tarli, C; Antonelli, M; Tosoni, A; D'Addio, S; Mirijello, A; Vassallo, Ga; Leggio, L; Gasbarrini, A; Addolorato, G; Gemelli Against COVID-19, Group; Armuzzi, A | |
| Frontiers in Drug Research and Development for Inflammatory Bowel Disease | 1-gen-2017 | Currò, D; Pugliese, D; Armuzzi, A | |
| Anti-TNF alpha therapy in the management of extraintestinal manifestation of inflammatory bowel disease | 1-gen-2012 | Andrisani, G; Guidi, L; Papa, A; Armuzzi, A | |
| Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis | 1-gen-2021 | Sandborn, W. J.; Feagan, B. G.; D'Haens, G.; Wolf, D. C.; Jovanovic, I.; Hanauer, S. B.; Ghosh, S.; Petersen, A.; Hua, S. Y.; Lee, J. H.; Charles, L.; Chitkara, D.; Usiskin, K.; Colombel, J.; Laine, L.; Danese, S.; Armuzzi, A; True North Study, Group | |
| A machine-learning parsimonious multivariable predictive model of mortality risk in patients with Covid-19 | 1-gen-2021 | Murri, R; Lenkowicz, J; Masciocchi, C; Iacomini, C; Fantoni, M; Damiani, A; Marchetti, A; Sergi, Pda; Arcuri, G; Cesario, A; Patarnello, S; Antonelli, M; Bellantone, R; Bernabei, R; Boccia, S; Calabresi, P; Cambieri, A; Cauda, R; Colosimo, C; Crea, F; De Maria, R; De Stefano, V; Franceschi, F; Gasbarrini, A; Parolini, O; Richeldi, L; Sanguinetti, M; Urbani, A; Zega, M; Scambia, G; Valentini, V; Armuzzi, A; Gremese, E; Gemelli against Covid, Group |
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile
Scopri
Tipologia
- 1 Contributo su Rivista27918
Data di pubblicazione
- In corso di stampa14
- 2020 - 20269653
- 2010 - 201911835
- 2000 - 20094579
- 1990 - 19991485
- 1980 - 1989329
- 1975 - 197923
Editore
- Edition AERCV1
- Elsevier1
- Futura Publishing Company1
- Grafica Luigi Monti s.r.l.1
- Karger, Basel1
- Mosby1
- sn1
- Springer-Verlag1
- Thieme1
Rivista
- DIGESTIVE AND LIVER DISEASE372
- EUROPEAN JOURNAL OF NUCLEAR MEDIC...267
- ANNALS OF ONCOLOGY244
- CANCERS232
- PLOS ONE223
- THE JOURNAL OF NUCLEAR MEDICINE222
- JOURNAL OF CLINICAL MEDICINE215
- EUROPEAN JOURNAL OF CANCER205
- GASTROINTESTINAL ENDOSCOPY197
- ALLERGY180
Keyword
- Humans2166
- Female1035
- Male996
- Middle Aged767
- Aged669
- Adult559
- COVID-19442
- Treatment Outcome373
- Animals329
- Retrospective Studies264
Lingua
- eng19972
- ita459
- spa14
- fre11
- ger8
- enm4
- por2
- chi1
Accesso al fulltext
- no fulltext25665
- reserved1362
- open891